ArticleBMC medical imaging2025
Non-Hodgkin's lymphoma classification using 3D radiomics machine learning models for precision imaging in oncology.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo apply quantitative imaging analysis for noninvasive classification of the most frequent subtypes of Non-Hodgkin Lymphoma (NHL) as a basis for a clinical imaging genomic model to support therapeutic monitoring and clinical decision making. MATERIALS AND
methodsIn this single-center study, 201 treatment-naïve patients with biopsy-proven NHL (50 diffuse large B-cell lymphoma [DLBCL], 51 mantle cell lymphoma [MCL], 49 follicular lymphoma [FL], and 51 chronic lymphocytic leukemia [CLL]) and 39 treatment-naïve non-small cell lung cancer patients with positron emission tomography (PET)/computed tomography (CT)-confirmed healthy axillary lymph nodes (LNs) were retrospectively analyzed. Three-dimensional (3D) segmentation and radiomic analysis of pathologically enlarged nodes (n = 1,628) were performed on contrast-enhanced CT scans, including healthy LNs as references. Feature selection was performed using a random forest (RF) classifier. Multiclass Classifier was performed using a Light Gradient Boosting Machine (LGBM) classifier for lymphoma subtype classification.
resultsPerformance to classify lymphoma from non-lymphoma and lymphoma subtypes was as follows: lymphoma vs. non-lymphoma: area under the curve (AUC) = 0.999; MCL vs. other NHL: AUC = 0.997; DLBCL vs. other NHL: AUC = 0.971; CLL vs. other NHL: AUC = 0.956; FL vs. other NHL: AUC = 0.892.
conclusionRadiomics combined with multiclass machine learning enables highly accurate, non-invasive differentiation of the major NHL subtypes on routine contrast-enhanced CT. By reliably separating indolent from aggressive phenotypes, this approach lays the groundwork for imaging-genomic models that could streamline biopsy guidance, enhance therapeutic monitoring, and advance precision oncology in lymphoma care.Conducted as a single-centre, retrospective proof-of-concept with internal patient-level cross-validation, these results are promising and form the basis for a prospective multicentre study to confirm generalisability and clinical utility. CLINICAL RELEVANCE STATEMENT: Accurate lymphoma classification is essential for predicting clinical behavior and guiding treatment. Imaging aids in disease staging, with quantitative analysis showing promise in predicting pathology and outcome. We explored machine learning on imaging features for lymphoma classification, thus enhancing clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.